Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cetuximab"" wg kryterium: Temat


Tytuł:
Homologous platelet gel on radiation-induced dermatitis in a patient receiving head and neck radiotherapy plus cetuximab: A case report.
Autorzy:
Guberti M; Nursing Research and EBP Unit - Health Professions Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Schiroli D; Transfusion Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Marraccini C; Transfusion Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Mazza G; Oncology Day Care Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Iotti C; Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Baricchi R; Transfusion Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Iotti B; Transfusion Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Merolle L; Transfusion Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Pokaż więcej
Źródło:
Medicine [Medicine (Baltimore)] 2023 Aug 25; Vol. 102 (34), pp. e34779.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Radiodermatitis*/etiology
Radiodermatitis*/therapy
Cetuximab*/therapeutic use
Antineoplastic Agents, Immunological*/therapeutic use
Squamous Cell Carcinoma of Head and Neck*/drug therapy
Squamous Cell Carcinoma of Head and Neck*/radiotherapy
Oropharyngeal Neoplasms*/drug therapy
Oropharyngeal Neoplasms*/radiotherapy
Complementary Therapies*/methods
Combined Modality Therapy ; Humans ; Male ; Aged ; Blood Platelets ; Gels
Czasopismo naukowe
Tytuł:
Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
Autorzy:
Altamura G; Department of Veterinary Medicine and Animal Productions, General Pathology and Pathologic Anatomy Section - University of Naples Federico II, Naples, Italy.
Martano M; Department of Veterinary Medicine and Animal Productions, General Pathology and Pathologic Anatomy Section - University of Naples Federico II, Naples, Italy.
Matrone A; Department of Veterinary Medicine and Animal Productions, General Pathology and Pathologic Anatomy Section - University of Naples Federico II, Naples, Italy.
Corteggio A; Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Naples, Italy.
Borzacchiello G; Department of Veterinary Medicine and Animal Productions, General Pathology and Pathologic Anatomy Section - University of Naples Federico II, Naples, Italy.
Pokaż więcej
Źródło:
Veterinary and comparative oncology [Vet Comp Oncol] 2024 Mar; Vol. 22 (1), pp. 149-155. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/veterinary
Carcinoma, Squamous Cell*/metabolism
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/veterinary
Mouth Neoplasms*/drug therapy
Mouth Neoplasms*/veterinary
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Cat Diseases*/drug therapy
Humans ; Animals ; Cats ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/veterinary ; Antibodies, Monoclonal/therapeutic use ; Vimentin ; Matrix Metalloproteinase 2/genetics ; Cell Line, Tumor ; Cadherins ; Epithelial-Mesenchymal Transition ; Cell Movement
Czasopismo naukowe
Tytuł:
A Real-World Retrospective Study to Evaluate the Reliability of Cetuximab plus Capecitabine versus Capecitabine as Maintenance Therapy in Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Autorzy:
Li J; The Second Department of Medical Oncology, Huizhou First Hospital, Huizhou, China.
Zhang H; The Second Department of Medical Oncology, Huizhou First Hospital, Huizhou, China.
Guo X; Department of Medical Oncology, The Central People's Hospital of Huizhou, Huizhou, China.
Dong S; Department of Medical Oncology, The Central People's Hospital of Huizhou, Huizhou, China.
Li Y; The Second Department of Medical Oncology, Huizhou First Hospital, Huizhou, China.
Huang W; The Second Department of Medical Oncology, Huizhou First Hospital, Huizhou, China.
Yuan X; The Second Department of Medical Oncology, Huizhou First Hospital, Huizhou, China.
Pokaż więcej
Źródło:
Medical principles and practice : international journal of the Kuwait University, Health Science Centre [Med Princ Pract] 2024; Vol. 33 (1), pp. 31-40. Date of Electronic Publication: 2023 Sep 19.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colonic Neoplasms*
Mice ; Animals ; Humans ; Cetuximab/therapeutic use ; Cetuximab/adverse effects ; Capecitabine/therapeutic use ; Retrospective Studies ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/therapeutic use ; Reproducibility of Results ; Fluorouracil/therapeutic use ; Fluorouracil/adverse effects ; Leucovorin/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Camptothecin/therapeutic use
Czasopismo naukowe
Tytuł:
Intraocular cetuximab: Safety and effect on axial elongation in young Guinea pigs with lens-induced myopization.
Autorzy:
Li HY; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Dong L; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Shi XH; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Zhang RH; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Zhou WD; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Wu HT; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yu CY; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Li YT; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Li YF; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Jonas JB; Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Molecular and Clinical Ophthalmology Basel, Switzerland.
Wei WB; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Electronic address: .
Liu YM; Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &Visual Sciences Key Lab, Beijing TongrenHospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Electronic address: .
Pokaż więcej
Źródło:
Experimental eye research [Exp Eye Res] 2024 Jan; Vol. 238, pp. 109715. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myopia*/metabolism
Lens, Crystalline*/metabolism
Guinea Pigs ; Animals ; Cetuximab/toxicity ; Cetuximab/metabolism ; Retina/metabolism ; Injections, Intraocular ; Disease Models, Animal
Czasopismo naukowe
Tytuł:
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Autorzy:
Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Ott PA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Ferris RL; Hillman Cancer Center, University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, USA.; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cascone T; University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Schadendorf D; Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, University Hospital Essen, Essen, Germany.
Le DT; Johns Hopkins University, Baltimore, Maryland, USA.
Sharma MR; University of Chicago, Chicago, Illinois, USA.
Barlesi F; Aix-Marseille University, Marseille, France.; Hopital de la Timone, Marseille, France.
Sharfman W; Johns Hopkins University, Baltimore, Maryland, USA.
Luke JJ; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Melero I; CIBERONC, and Clinica Universidad de Navarra, Pamplona, Spain.
Lathers D; Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA.
Neely J; Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA.
Suryawanshi S; Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA.
Sanyal A; Boston Scientific, Marlborough, Massachusetts, USA.
Holloway JL; Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA.
Suryawanshi R; Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA.
Ely S; Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA.
Segal NH; Memorial Sloan Kettering Cancer Center, New York, New York, USA .; Weill Cornell Medical College, New York, NY, USA.
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Mar 07; Vol. 12 (3). Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Melanoma*
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/chemically induced
Head and Neck Neoplasms*/drug therapy
Humans ; Nivolumab/pharmacology ; Nivolumab/therapeutic use ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/drug therapy
Czasopismo naukowe
Tytuł:
Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies.
Autorzy:
Bilemjian V; Surflay Nanotec GmbH, 12489, Berlin, Germany.; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Lin Y; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Wan W; Surflay Nanotec GmbH, 12489, Berlin, Germany.
Egri G; Surflay Nanotec GmbH, 12489, Berlin, Germany.
Huls G; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Heinze T; Friedrich Schiller University Jena, Institute of Organic Chemistry and Macromolecular Chemistry, Center of Excellence for Polysaccharide Research, 07743, Jena, Germany.
Bremer E; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Gericke M; Friedrich Schiller University Jena, Institute of Organic Chemistry and Macromolecular Chemistry, Center of Excellence for Polysaccharide Research, 07743, Jena, Germany.
Dähne L; Surflay Nanotec GmbH, 12489, Berlin, Germany.
Pokaż więcej
Źródło:
Chembiochem : a European journal of chemical biology [Chembiochem] 2024 Mar 01; Vol. 25 (5), pp. e202300828. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Xylans*
Polysaccharides*
Humans ; Antibody Specificity ; Biological Assay ; Carbonates ; Cetuximab/pharmacology
Czasopismo naukowe
Tytuł:
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
Autorzy:
Ciardiello D; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy; Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
Mauri G; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy; Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milano, Italy; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Sartore-Bianchi A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy; Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Division of Clinical Research and Innovation, Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Siena S; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy; Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Zampino MG; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Fazio N; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Cervantes A; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Pokaż więcej
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2024 Mar; Vol. 124, pp. 102683. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Colonic Neoplasms*/drug therapy
Rectal Neoplasms*/drug therapy
Humans ; Retrospective Studies ; Antibodies, Monoclonal/therapeutic use ; Cetuximab ; Proto-Oncogene Proteins B-raf/genetics
Czasopismo naukowe
Tytuł:
Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment.
Autorzy:
Arantes LMRB; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
Silva-Oliveira RJ; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos, Brazil.
de Carvalho AC; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
Melendez ME; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.; Molecular Carcinogenesis Program, National Cancer Institute - INCA, Rio de Janeiro, Brazil.
Sorroche BP; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
de Jesus Teixeira R; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
Tostes K; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
Palmero EI; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.; Department of Genetics, Brazilian National Cancer Institute - INCA, Rio de Janeiro, Brazil.
Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.; Life and Health Sciences Research Institute - ICVS, Health Sciences School, University of Minho - Braga, Braga, Portugal.
Carvalho AL; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, Brazil.
Pokaż więcej
Źródło:
Head & neck [Head Neck] 2024 Mar; Vol. 46 (3), pp. 461-472. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/genetics
Carcinoma, Squamous Cell*/metabolism
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/genetics
Acrylamides*
Quinazolines*
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/genetics ; Afatinib ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; ErbB Receptors/metabolism ; Cell Line, Tumor ; DNA Modification Methylases/genetics ; DNA Modification Methylases/therapeutic use ; Tumor Suppressor Proteins ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/therapeutic use
Czasopismo naukowe
Tytuł:
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
Autorzy:
van Veggel BAMH; Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van der Wekken AJ; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
Paats MS; Department of Pulmonary Diseases, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
Hendriks LEL; Department of Pulmonary Diseases, Maastricht University Medical Center, Maastricht, the Netherlands.
Hashemi SMS; Department of Pulmonary Medicine, Amsterdam University Medical Centers, Vrije Universiteit Medical Center, and Cancer Center Amsterdam, Amsterdam, the Netherlands.
Daletzakis A; Department of Biometrics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Bosch LJW; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Monkhorst K; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands.
de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Mar 01; Vol. 130 (5), pp. 683-691. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Female ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Male ; Afatinib/therapeutic use ; Cetuximab/adverse effects ; ErbB Receptors/genetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Exons ; Mutation ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Tytuł:
Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC.
Autorzy:
Song PN; Department of Radiology, The University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.; Graduate Biomedical Sciences, The University of Alabama at Birmingham, Birmingham, USA.
Lynch SE; Department of Radiology, The University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.; Graduate Biomedical Sciences, The University of Alabama at Birmingham, Birmingham, USA.
DeMellier CT; Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA.
Mansur A; Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA.
Gallegos CA; Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA.
Wright BD; Department of Radiology, The University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.
Hartman YE; Department of Otolaryngology, The University of Alabama at Birmingham, Birmingham, USA.
Minton LE; Department of Otolaryngology, The University of Alabama at Birmingham, Birmingham, USA.
Lapi SE; Department of Radiology, The University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.; O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, USA.
Warram JM; Department of Radiology, The University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.; Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA.; Department of Otolaryngology, The University of Alabama at Birmingham, Birmingham, USA.; O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, USA.
Sorace AG; Department of Radiology, The University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA. .; Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA. .; O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 14; Vol. 14 (1), pp. 3771. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Head and Neck Neoplasms*/drug therapy
Humans ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Cell Line, Tumor ; Tumor Microenvironment ; ErbB Receptors
Czasopismo naukowe
Tytuł:
Rhamnose modified antibodies show improved immune killing towards EGFR-positive solid tumor cells.
Autorzy:
Hong H; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China.
Zhao J; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China.
Zhou K; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China.
Li Y; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China.
Li D; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China.
Wu Z; Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122, Wuxi, China. Electronic address: .
Pokaż więcej
Źródło:
Carbohydrate research [Carbohydr Res] 2024 Feb; Vol. 536, pp. 109038. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Rhamnose*/pharmacology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Animals ; Humans ; Mice ; Cetuximab/pharmacology ; Antibodies, Monoclonal/pharmacology ; ErbB Receptors ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
Autorzy:
Jones VT; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Graves-Deal R; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Cao Z; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Bogatcheva G; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Ramirez MA; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Harmych SJ; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, 37232, USA.
Higginbotham JN; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Sharma V; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Damalanka VC; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
Wahoski CC; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.; Program in Cancer Biology, Vanderbilt University, Nashville, TN, 37232, USA.
Joshi N; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Irudayam MJ; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.
Roland JT; Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Ayers GD; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Liu Q; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Coffey RJ; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA.; Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Janetka JW; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
Singh B; Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN, 37232-0441, USA. .; Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .
Pokaż więcej
Źródło:
Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2024 Jan 12; Vol. 81 (1), pp. 28. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji:
Journal Article
MeSH Terms:
Signal Transduction*
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/metabolism
Humans ; Cetuximab/pharmacology ; Proto-Oncogene Proteins c-met/genetics ; Proto-Oncogene Proteins c-met/metabolism ; Drug Resistance, Neoplasm/genetics ; Protease Inhibitors/pharmacology ; Peptide Hydrolases/metabolism ; Cell Line, Tumor ; Hepatocyte Growth Factor/genetics ; Hepatocyte Growth Factor/metabolism ; Hepatocyte Growth Factor/pharmacology
Czasopismo naukowe
Tytuł:
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Autorzy:
Wang HM; Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital/College of Medicine, Chang Gung University, Taoyuan, Taiwan, ROC.
Lou PJ; Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, ROC.
Yang MH; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chen TH; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Lien MY; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, ROC.
Lin JC; Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan, ROC.
Chen JP; Department of Oncology, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan, ROC.
Lu WC; Department of Oncology, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan, ROC.
Lu HJ; Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital/College of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC.
Huang TL; Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital/College of Medicine, Chang Gung University, Kaohsiung, Taiwan, ROC.
Yen CJ; Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan, ROC.
Wu SY; Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan, ROC.
Wang HC; Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC.
Hsieh MC; Department of Hematology and Oncology, E-Da Cancer Hospital/College of Medicine, I-Shou University, No.21, E-Da Rd., Yan-Chao Dist., Kaohsiung, 807, Taiwan, ROC. .
Pokaż więcej
Źródło:
Targeted oncology [Target Oncol] 2024 Jan; Vol. 19 (1), pp. 51-58. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Head and Neck Neoplasms*/drug therapy
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Retrospective Studies ; Neoplasm Recurrence, Local/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Synthesis and preclinical evaluation of [C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor.
Autorzy:
Högnäsbacka, Antonia A. (AUTHOR)
Poot, Alex J. (AUTHOR)
Plisson, Christophe (AUTHOR)
Bergare, Jonas (AUTHOR)
Bonsall, David R. (AUTHOR)
McCluskey, Stuart P. (AUTHOR)
Wells, Lisa A. (AUTHOR)
Kooijman, Esther (AUTHOR)
Schuit, Robert C. (AUTHOR)
Verlaan, Mariska (AUTHOR)
Beaino, Wissam (AUTHOR)
van Dongen, Guus A. M. S. (AUTHOR)
Vugts, Danielle J. (AUTHOR)
Elmore, Charles S. (AUTHOR)
Passchier, Jan (AUTHOR)
Windhorst, Albert D. (AUTHOR)
Pokaż więcej
Źródło:
EJNMMI Research. 2/16/2024, Vol. 14, p1-15. 15p.
Czasopismo naukowe
Tytuł:
Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Autorzy:
Liu YF; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Department of Colorectal Surgery, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China.
Feng ZQ; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Department of Colorectal Surgery, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China.
Chu TH; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Department of Colorectal Surgery, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China.
Yi B; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Department of Colorectal Surgery, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China.
Liu J; Department of Radiology, The Fourth Central Hospital Affiliated to Nankai University, Tianjin 300241, China.
Yu H; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Xue J; Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China.
Wang YJ; Laboratory of Oncologic molecular medicine, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China. Electronic address: yijiawang_.
Zhang CZ; Department of Colorectal Surgery, Tianjin Union Medical Center, 190 JieYuan Road, Tianjin 300121, China. Electronic address: .
Pokaż więcej
Źródło:
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2024 Apr; Vol. 126, pp. 155462. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Proto-Oncogene Proteins c-akt*/metabolism
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Diterpenes*
Animals ; Humans ; Cetuximab/pharmacology ; Cetuximab/genetics ; Cetuximab/metabolism ; beta Catenin/metabolism ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism ; ErbB Receptors/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Wnt Signaling Pathway ; Mutation
Czasopismo naukowe
Tytuł:
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Autorzy:
Guigay J; Partnerships and Clinical Development - Early Assets, GORTEC, Tours, France. Electronic address: .
Ortholan C; Oncology-Radiotherapy Unit, Hospital Centre Princesse-Grace, Monaco.
Vansteene D; Medical Oncology Unit, West Cancerology Institute, Saint Herblain, France.
Cupissol D; Medical Oncology Unit, Cancer Institute of Montpellier, Montpellier, France.
Even C; Medical Oncology Unit, Gustave-Roussy Institute, Villejuif, France.
Kaminsky MC; Medical Oncology Unit, Lorraine Cancerology Institute, Nancy, France.
Sire C; Oncology-Radiotherapy Unit, Hospital Group South Bretagne, Lorient, France.
Blot E; Medical Oncology Unit, ELSAN Group, Private Hospital Océane, Vannes, France.
Debourdeau P; Medical Oncology Unit, Sainte Catherine Institute, Avignon, France.
Bozec L; Medical Oncology Unit, Curie Institute, Saint Cloud, France.
Saada-Bouzid E; Medical Oncology and Research Department, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
Fayette J; Medical Oncology Unit, Cancer Research Centre Léon Bérard, Lyon, France.
Dalloz P; Medical Oncology Unit, Centre Jean Perrin, Clermont-Ferrand, France.
Pointreau Y; Radiation Oncology Unit, ILC (Inter-regional Cancerology Institute) - Jean Bernard Center & Victor Hugo Private Clinic, Sarthe Cancer Center, Le Mans, France.
Caer HL; Medical Oncology Unit, Hospital Centre of Saint-Brieuc, Saint-Brieuc, France.
Falandry C; Medical Oncology Unit, Hospital Centre of South Lyon, Pierre Bénite, France.
Digue L; Medical Oncology Unit, Saint André Universitary Hospital of Bordeaux, Bordeaux, France.
Braccini A; Medical Oncology Unit, Centre Azuréen de Cancérologie, Mougins, France.
Lopez S; Medical Oncology Unit, Hospital Centre of Annecy Genevois, Pringy, France.
Guillet P; Medical Oncology Unit, Intercommunal Hospital Centre, La Seyne sur Mer, France.
Michel C; Medical Oncology and Research Department, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
Cheurfa N; Biostatistics and Epidemiology Unit, Gustave Roussy, Inserm U1018 Oncostat, Labelled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.
Schwob D; Biostatistics and Epidemiology Unit, Gustave Roussy, Inserm U1018 Oncostat, Labelled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.
Bourhis J; Radiotherapy Unit, Universitary Hospital Center of Vaudois, Lausanne, Switzerland.
Mertens C; Oncogeriatrics Unit, Bergonié Institute, Bordeaux, France.
Aupérin A; Biostatistics and Epidemiology Unit, Gustave Roussy, Inserm U1018 Oncostat, Labelled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.
Pokaż więcej
Corporate Authors:
ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC
Źródło:
The lancet. Healthy longevity [Lancet Healthy Longev] 2024 Mar; Vol. 5 (3), pp. e182-e193.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Methotrexate*/adverse effects
Head and Neck Neoplasms*/drug therapy
Humans ; Male ; Aged ; Female ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Cetuximab/adverse effects ; Frail Elderly ; Disease Progression ; Fatigue
Czasopismo naukowe
Tytuł:
Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis.
Autorzy:
Jiang Y; Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.; Nanjing University of Chinese Medicine, Nanjing, China.
Zhao M; Center for Pharmacoeconomics and Outcomes Research & Department of Public Affairs Management, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Tang W; Center for Pharmacoeconomics and Outcomes Research & Department of Public Affairs Management, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China. .
Zheng X; Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 09; Vol. 24 (1), pp. 188. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Proto-Oncogene Proteins p21(ras)*
Humans ; Cetuximab/therapeutic use ; Network Meta-Analysis ; Quality of Life ; Systematic Reviews as Topic
Czasopismo naukowe
Tytuł:
Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.
Autorzy:
Pitakpaiboonkul P; Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Jiarpinitnun C; Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Pattaranutaporn P; Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Ngamphaiboon N; Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (4), pp. e7047.
Typ publikacji:
Journal Article
MeSH Terms:
Platinum*/therapeutic use
Head and Neck Neoplasms*/drug therapy
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/chemically induced ; Cetuximab ; Retrospective Studies ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis.
Autorzy:
Song Y; Department of Intensive Care Unit, the First Affiliated Hospital of Shandong Traditional Medical University, 250000, Jinan, China.
Mao Q; Department of Oncology, School of Medicine, Zhongda Hospital, Southeast University, No. 87 Dingjiaqiao Road, 210009, Nanjing, Jiangsu Province, China.
Zhou M; Department of Oncology, Shenzhen Longhua District Central Hospital, Shenzhen, China.
Liu CJ; Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, 246000, Anqing, AnHui, China. .
Kong L; Department of Intensive Care Unit, the First Affiliated Hospital of Shandong Traditional Medical University, 250000, Jinan, China. .
Hu T; Department of General Practice, Anqing Municipal Hospital, 246000, Anqing, AnHui, China.
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2024 Feb 01; Vol. 24 (1), pp. 58. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Colorectal Neoplasms*/pathology
Colonic Neoplasms*
Rectal Neoplasms*
Humans ; Middle Aged ; Aged ; Bevacizumab/therapeutic use ; Cetuximab/therapeutic use ; Panitumumab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies